Professor Deepak Bhatt gave us a brief recap of some data he presented at the ACC Late-Braker session. He presented data about a drug know as Bentracimab,which it is an investigational agent, a human monoclal antibody that it is been desigend to reverse the effect of the anti-platelet drug Ticagrelor.

Video: https://congressreport.eu/scientific-contents/interview:bentracimab-immediately-and-significantly-reverses-antiplatelet-effects-ticagrelor-older-people

Professor John Camm recently attended the European Heart Rhythm Association annual congress.  One of the session he involved in wanted to group together the challenging cases in the topic.

Video: https://congressreport.eu/scientific-contents/interview:protecting-comorbid-patients-atrial-fibrillation-stroke

Professor Manesh Patel speak about how to reduce limb events, amputations and making our patients limbs to better with peripheral arterial disease.

Video: https://congressreport.eu/scientific-contents/interview:how-reduce-limb-events-including-amputations-our-patients

Professor David Lanfear summarize the key interesting things from the American College of Cardiology 2022 Scientific sessions in the topic.

Video: https://congressreport.eu/scientific-contents/interview:guidance-heart-failure-care-acc-2022

Professor Cecilia Linde gave us an update from the European Heart Rhythm Association conference from Copenhagen on four topics regarding the EHRA scientific documents.

1. Interaction between electrical implantable devices and medical procedures

2. Mitral valve prolapse

3. Novel oral anticoagulants, NOACs

4. Leadless Pacemaker

Video: https://congressreport.eu/scientific-contents/interview:ehra-scientific-documents-2022

Professor Florian Rader presented this year at ACC 2022 the results of the MAVA-LTE Study. As the backdrop of this study, Hypertrophic Cardiomyopathy is a disease known for now over 70 years, and in these years we haven't had any specific medication  that targets the underline mechanism of this disorder.

Video: https://congressreport.eu/scientific-contents/interview:updated-cumulative-results-treatment-mavacamten-explorer-lte-cohort-mava-lte-study

Prof. David F. McDermott shared his thoughts in the kidney cancer filed. What was the biggest changes in the last six months?

Video: https://congressreport.eu/scientific-contents/standalonecontent:role-immune-checkpoint-inhibitors-and-vegf-tkis-adjuvant-treatment-renal-cell-carcinoma

Prof. Camillo Porta shared his thoughts on the ASCO GU 2022 meeting which focused on the renal cell carcinoma updates. Which were those changes what we can apply in our daily practice?

Video: https://congressreport.eu/scientific-contents/standalonecontent:how-will-current-therapeutic-options-change-treatment-rcc-daily-practice

Professor Stefan N. Symeonides gave us a talk about the results from 30-month follow-up of KEYNOTE-564.

Video: https://congressreport.eu/scientific-contents/standalonecontent:pembrolizumab-post-nephrectomy-adjuvant-therapy-patients-renal-cell-carcinoma

Professor Oliver Sartor gave us a talk about the newer concepts around the treatment intensification in prostate cancer, focus a little bit on the newer darolutamide and a PARP inhibitor studies.

Video: https://congressreport.eu/scientific-contents/standalonecontent:treatment-intensification-treatment-prostate-cancer